European Pharmaceutical Review

JANUARY 24, 2024

Topline data from a novel Phase III study show that the biologic TREMFYA ® (guselkumab) facilitated rapid and significant clearance in moderate to severe scalp psoriasis ( PsO ) and significant improvement in scalp itch at 16 weeks, according to Johnson & Johnson. percent compared to 37.8 percent versus 33.4 percent compared to 37.8

80

80

Pharmaceutical Technology

MARCH 18, 2024

Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

Biosimilars 40

Biosimilars 40

Outsourcing Pharma

FEBRUARY 15, 2024

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

59

59

European Pharmaceutical Review

MARCH 28, 2023

The European Commission (EC) has approved Sotyktu (deucravacitinib), a first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis. Data that supported the approval EC’s approval was based on results from Bristol Myers Squibb’s Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials.

Dosage 93

Dosage Immunity Immunization 93

European Pharmaceutical Review

JANUARY 11, 2024

The biologic targets the p40 protein, which has key roles in treating immune-mediated diseases like Crohn’s disease, psoriasis as well as psoriatic arthritis, Alvotech highlighted. Uzpruvo is produced in Sp2/0 cells via perfusion, in the same way that the reference product Stelara is.

Biosimilars 102

Biosimilars Immunity Immunization 102

Pharmacy Times

JULY 18, 2022

Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

49

49

pharmaphorum

FEBRUARY 1, 2021

It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body can have skin lesions. It’s not the first time that Almirall has partnered with a digital health specialist to develop tools that complement its drug therapies for psoriasis.

124

124

LifeProNow

MARCH 12, 2023

The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines. The mission of the partnership is to improve the lives of dermatology patients with access to innovative clinical trials and the launch of new medicines.

244

244

European Pharmaceutical Review

APRIL 30, 2024

The committee also recommended the biosimilar medicine Wezenla (ustekinumab) to treat of plaque psoriasis. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease. Generic medicine Eribulin Baxter (eribulin) was also granted a positive opinion by the committee, to treat breast cancer and liposarcoma.

Biosimilars 93

Biosimilars Generic Medicine Chemotherapy Hospitals 93

Pharmaceutical Technology

DECEMBER 20, 2023

Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

40

40

Outsourcing Pharma

MARCH 24, 2022

The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

DECEMBER 5, 2023

ONO-4685 is under clinical development by Ono Pharmaceutical and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris).

40

40

European Pharmaceutical Review

DECEMBER 14, 2022

a wholly-owned subsidiary of Nimbus Therapeutics and Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) inhibitor NDI-034858, an oral, potential best-in-class selective allosteric TYK2 inhibitor for multiple autoimmune diseases following successful recent Phase IIb results in psoriasis. For $4 billion , Takeda will acquire Nimbus Lakshmi, Inc.,

85

85

European Pharmaceutical Review

JULY 4, 2023

JNJ-2113, the first and only oral interleukin-23 receptor (IL-23R) antagonist peptide in development for moderate-to-severe plaque psoriasis (PsO) has demonstrated positive results in a Phase II trial. How does Janssen’s oral IL-23R antagonist for plaque psoriasis work? at the World Congress of Dermatology 2023. .

74

74

Pharmaceutical Technology

SEPTEMBER 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb ’s (BMS) Sotyktu (deucravacitinib) to treat adult patients with moderate-to-severe plaque psoriasis. The approval is based on data from the Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials.

98

98

Express Pharma

MAY 30, 2023

ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The post Sun Pharma gets China NMPA approval for ILUMETRI to treat moderate-to-severe plaque psoriasis appeared first on Express Pharma.

92

92

Express Pharma

AUGUST 1, 2023

Janssen Pharmaceuticals recently announced its latest clinical trial results of JNJ-2113, the novel, first-in-class oral interleukin 23 receptor (IL-23R) antagonist peptide in adult patients with moderate-to-severe plaque psoriasis (PsO). per cent for the placebo group, and 37.2 per cent, 58.1 per cent, 51.2 per cent, 65.1

Dosage 52

Dosage 52

Outsourcing Pharma

MAY 26, 2023

The first patients with psoriasis have been dosed with a new drug to help combat the inflammatory skin disease in a clinical trial in China.

52

52

Pharmafile

APRIL 12, 2023

ALM) , a global biopharmaceutical company focused on skin health, today announced the publication in the British Medical Journal (BMJ) of the POSITIVE study protocol, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint. April 12, 2023 – Almirall, S.A. read more

52

52

pharmaphorum

OCTOBER 26, 2022

Psoriasis is a tricky disease to manage, as drawbacks and side effects loom with each and every type of treatment. Anyone who watches television has heard the list of potential adverse reactions, considering that commercials for psoriasis treatments are seemingly only outnumbered by goofy ads for auto insurance. Manage it early.

Immunity 98

Immunity Immunization Adverse Reactions 98

Pharmaceutical Business Review

MAY 1, 2023

The next generation topical phosphodiesterase-4 (PDE4) inhibitor Zoryve is also indicated to treat psoriasis in the intertriginous areas. We are proud to bring this important new steroid-free cream to Canada, where there is a need for safe and effective topical treatment for plaque psoriasis. “We

Adverse Reactions 52

Adverse Reactions Immunity Immunization 52

PharmaShots

JANUARY 23, 2023

The specific mechanisms by which VTAMA cream exerts its therapeutic action in psoriasis patients are unknown. Until recently, there were very few topical options available for treating plaque psoriasis long-term. Smriti: Brief us about the study design of the P-III clinical trial evaluating VTAMA cream. of VTAMA cream?

Labelling 40

Labelling Immunity Immunization 40

Pharma Mirror

SEPTEMBER 16, 2022

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study, which resembled real-life clinical practice. In this study, Ilumetri®?

52

52

pharmaphorum

DECEMBER 22, 2021

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted rival deucravacitinib, which could make its debut next year. The post Amgen builds Otezla’s psoriasis label as rival BMS looms large appeared first on.

Labelling 59

Labelling 59

PharmaShots

JUNE 22, 2023

in patients with HS The results showed a clinical improvement for patients who completed the planned 16wks. The results were consistent with the results from the P-IIb dose-finding study (IASOS) in psoriasis The results will be presented at an upcoming scientific conference. of treatment, improvements incl.

53

53

Pharmaceutical Technology

JULY 12, 2022

Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials.

Labelling 64

Labelling Immunity Immunization 64

European Pharmaceutical Review

JUNE 29, 2023

This is relevant in Crohn’s disease, ulcerative colitis and chronic skin disease psoriasis. Previous research has shown that blocking interleukin-23 with specific therapeutic antibodies is very effective in psoriasis and Crohn’s disease. Mirikizumab is the first such antibody tested for ulcerative colitis. percent versus 13.3

90

90

European Pharmaceutical Review

APRIL 26, 2024

Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.

Biosimilars 87

Biosimilars Packaging Pharmaceutical Companies Pharmaceutical Companies 87

Express Pharma

JULY 14, 2023

The MAA submission is based on results from the phase III multi-regional clinical trials in patients with plaque psoriasis. The primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms.

Biosimilars 88

Biosimilars 88

PharmaShots

APRIL 17, 2023

Daniel Quirk: Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that affects approximately 7.5 Daniel Quirk: Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that affects approximately 7.5 million people in the United States. million people in the United States.

Immunity 40

Immunity Immunization Hospitals 40

pharmaphorum

JULY 19, 2021

During the last two decades, the landscape for psoriasis treatment has exploded. Suddenly, those with more severe psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin. National Psoriasis Foundation found 52% of patients with psoriasis are dissatisfied with treatment.

Diabetes 59

Diabetes 59

pharmaphorum

MAY 25, 2022

Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in the treatment of the skin disorder. It’s also in clinical testing for atopic dermatitis or eczema, with results due next year.

Labelling 52

Labelling Biosimilars 52

European Pharmaceutical Review

NOVEMBER 2, 2023

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Like Stelara, the most serious known side effect of Wezlana is infection.

Biosimilars 91

Biosimilars 91

Pharmacy Times

NOVEMBER 10, 2023

The sBLA was based on data from a clinical study assessing the pharmacokinetics of switching between adalimumab and adalimumab-bwwd for patients with moderate to severe plaque psoriasis.

26

26

pharmaphorum

OCTOBER 31, 2022

Shares in French biotech Inventiva were on the slide this morning after AbbVie revealed that it had decided to abandon development of cedirogant, their drug candidate for autoimmune diseases including psoriasis. billion-plus product if approved.

52

52

Pharmaceutical Technology

DECEMBER 14, 2022

The acquisition of this programme is expected to boost the growing late-stage pipeline, gastrointestinal (GI) clinical programmes and therapeutic focus of Takeda. In November, Nimbus reported positive topline data from a Phase IIb clinical trial of NDI-034858 in moderate-to-severe plaque psoriasis patients.

Immunity 59

Immunity Immunization 59

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 64

Diabetes Immunity Immunization Biosimilars 64